The estimated Net Worth of Charles R Schaller is at least $208 mil dollars as of 9 September 2010. Charles Schaller owns over 5,000 units of Celldex Therapeutics stock worth over $208,200 and over the last 16 years Charles sold CLDX stock worth over $0.
Charles has made over 4 trades of the Celldex Therapeutics stock since 2008, according to the Form 4 filled with the SEC. Most recently Charles bought 5,000 units of CLDX stock worth $17,250 on 9 September 2010.
The largest trade Charles's ever made was buying 10,000 units of Celldex Therapeutics stock on 10 November 2009 worth over $51,600. On average, Charles trades about 5,000 units every 133 days since 2008. As of 9 September 2010 Charles still owns at least 5,000 units of Celldex Therapeutics stock.
You can see the complete history of Charles Schaller stock trades at the bottom of the page.
Charles's mailing address filed with the SEC is 4072 SPRING ISLAND DRIVE, , OKATIE, SC, 29909.
Over the last 16 years, insiders at Celldex Therapeutics have traded over $19,527,314 worth of Celldex Therapeutics stock and bought 273,450 units worth $1,157,166 . The most active insiders traders include Rajesh B Parekh, Garry Arthur Neil, eInc Medarex. On average, Celldex Therapeutics executives and independent directors trade stock every 69 days with the average trade being worth of $1,750,671. The most recent stock trade was executed by Samuel Bates Martin on 14 June 2024, trading 20,169 units of CLDX stock currently worth $204,917.
celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im
Celldex Therapeutics executives and other stock owners filed with the SEC include: